Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations – the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Ultratech Cement Ltd - Q2FY18 Result Update - Kotak
NIIT Technologies Ltd - Q2FY18 Result Update - Kotak
Tata Sponge Iron Ltd - Q2FY18 Result Update - Kotak
Bajaj Auto - Q2FY18 Result Update - Kotak
Blue Dart Express Ltd - Q2FY18 Result Update - Kotak
Axis Bank Q2FY18 Result Update Rating - NEUTRAL - Arihant Capital Markets
Federal Bank Q2FY18 Result Update - Rating - HOLD - Arihant Capital Markets
DCB Bank Q2FY18 Result Update - Rating - HOLD - Arihant Capital Markets
Endurance Technologies Ltd - Initiating Coverage - A Healthy Upward Ride - Angel Broking
Karnataka Bank Q2FY18 Result Update - Rating - HOLD - Arihant Capital Markets
The Pitch Report - Call Update: Bombay Burmah Trading Corporation - BUY - TP Rs.2025
Views on Wipro Limited Q2FY2018 Results: Angel Broking
IndusInd Bank Q2FY18 Result Update - Rating - HOLD - Arihant Capital Markets
Insurance: Select large players drive growth - Kotak
Views on Tata Consultancy Services Limited Q2FY2018 Results: Angel Broking
Metals & Mining (Attractive): 2QFY18 preview-good for all - Kotak
Energy: 2QFY18E preview—strong quarter across the board - Kotak
South Indian Bank (SIB IN) - Earnings update - PAT declined owing to exceptional provision - CSEC Research
The Pitch Report - Call Update: BBTC - ACCUMULATE - TP Rs.1613 - Kotak
Result Update: Cyient Ltd - ACCUMULATE - TP Rs.576 - Kotak
Result Update: TV18 Broadcast Ltd - BUY - TP Rs.50 - Kotak
Lakshmi Vilas Bank (LVB IN) - Earnings update - Provisions surged leading to steep fall in PAT - CSEC Research
Cement prices - on a weak footing - Kotak
Company Update: Engineers India Ltd - BUY - TP Rs.182 - Kotak
Company Update: Insecticides (India) Ltd - SELL - TP Rs.830 - Kotak
Logistics: Another blow to the e-way bill and thus to prospects of formalizing the sector - Kotak
Cement: 2QFY18 preview-healthy volumes, costs outweigh realizations - Kotak
Company Update: Time Technoplast Ltd - ACCUMULATE - TP Rs.216 - Kotak
Bumper profits ahead for Natco Pharma: Angel Broking
Banks : More questions than answers : New pricing regime likely to be introduced to replace MCLR/base rate - Kotak
Economy: RBI retains inflation focus - Kotak
BFSI : 2QFY18 preview: muted quarter for banks; stronger for NBFCs - Kotak
Telecom: LTE - 40% of data users, 80%+ of usage - Kotak
Energy - OMCs (BPCL | HPCL | IOCL): Some relief, but not enough - Kotak
Auto sales numbers for the month of September: Angel Broking
Technology: Accenture FY2018 guidance signals no change in demand trend - Kotak
Stock Picks - Maruti Suzuki, Federal Bank - Arihant Capital Market
Company Update: Gujarat Alkalies & Chemicals (GACL) - SELL - TP Rs.540 - Kotak
Stock Picks - Hero MotoCorp, Ultratech Cement - Arihant Capital Markets
Company Update: Maruti Suzuki India Limited (MSIL) - BUY - TP Rs.9061 - Kotak
Power: Monthly Tracker, September 2017 - Kotak
Consumer Products (Cautious): Observations: field trip to Patna - Kotak
Reliance Home Finance (RHFL) listed today and it is trading at 4.6x FY2017 book value: Angel Broking
Stocks Picks - TVS Motors, TCS & DCB Bank - Arihant Capital Markets Ltd
Result Update: AksharChem India Ltd - ACCUMULATE - TP Rs.800 - Kotak
Initiating Coverage: VIP Industries Ltd - BUY - TP Rs.325 - Kotak
Company Update: KNR Constructions Ltd - BUY - TP Rs.236 - Kotak
Top Stock Picks by Arihant Capital Market
Chhota (to) MOTA ideas - CALL UPDATE: Venky's India Ltd - BUY - TP Rs.2650 - Kotak
Gabriel India Limited (GABR IN) - Shift in strategy to accelerate the growth - Initiating Coverage - CSEC Research


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017